Another life sciences company is launching in Philadelphia: VintaBio came out of “stealth” mode Tuesday with the announcement of a $64 million investment led by Decheng Capital, and the aim of serving the growing cell and gene therapy industry.
The Navy Yard-based company’s primary goal is to ease the flow of manufacturing for these cell and gene therapy companies, and has opened a 22,500-square-foot facility to do so.
The company was founded by University of Pennsylvania researchers Junwei Sun and Dr. Shangzhen Zhou. The pair developed the first viral vectors used for life-saving therapies, including for the first pediatric patient to receive CAR T-Cell therapy. They are also behind Penn’s Center for Advanced Retinal and Ocular Therapeutics (CAROT) and the CAROT Research Vector Core, respectively.
READ FULL ARTICLE HERE
